HFpEF and 2-year Mortality of COPD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-01

Study Completion Date

2025-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to assess potential relationship between heart failure with preserved ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Change in Airway Peripheral Tone in COPD

NCT04166812

COPD COPD, Early-Onset

UNKNOWN

Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement

NCT02346292

COPD

COMPLETED

Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

NCT05922202

Role of Frailty in COPD

RECRUITING

Clinical Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure (CHF)

NCT01114386

COPD Heart Failure, Congestive

COMPLETED

Long-Term Study On Home Spirometry After Lung Transplantation

NCT00743171

Lung Transplantation Rejection Death +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal cardiac function

Cardiac function assessment

Intervention Type DIAGNOSTIC_TEST

Echocardiography, cardiac enzymes analysis

Heart failure with reduced ejection fraction

Cardiac function assessment

Intervention Type DIAGNOSTIC_TEST

Echocardiography, cardiac enzymes analysis

Heart failure with preserved ejection fraction

Cardiac function assessment

Intervention Type DIAGNOSTIC_TEST

Echocardiography, cardiac enzymes analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac function assessment

Echocardiography, cardiac enzymes analysis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Exacerbation of chronic obstructive pulmonary disease requiring hospitalization

Age 40 - 80 years

Performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG)

Long acting beta agonist (LABA)/ long acting antimuscarinic (LAMA) bronchodilator treatment

Exclusion Criteria

Presence of major heart valve dysfunction

Documented noncompliance with treatment

Presence of active malignancy

Body mass index \> 40

Interstitial lung disease

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No